BR0017136A - Peptìdeos de ligação ao hla e seus usos. - Google Patents

Peptìdeos de ligação ao hla e seus usos.

Info

Publication number
BR0017136A
BR0017136A BR0017136-0A BR0017136A BR0017136A BR 0017136 A BR0017136 A BR 0017136A BR 0017136 A BR0017136 A BR 0017136A BR 0017136 A BR0017136 A BR 0017136A
Authority
BR
Brazil
Prior art keywords
hla
peptides
binding peptides
allele
binding
Prior art date
Application number
BR0017136-0A
Other languages
English (en)
Inventor
Alessandro Sette
John Sidney
W Martin Kast
Scott Southwood
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of BR0017136A publication Critical patent/BR0017136A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"PEPTìDEOS DE LIGAçãO AO HLA E SEUS USOS". A presente invenção proporciona os meios e os métodos para selecionar peptídeos imunogênicos e as composições de peptídeos imunogênicos capazes de ligar especificamente glicoproteínas codificadas por alelos de HLA e induzir a ativação das células T em células T restringidas pelo alelo. Os peptídeos são úteis para fazer surgir uma resposta imunológica contra um antígeno desejado.
BR0017136-0A 2000-02-23 2000-02-23 Peptìdeos de ligação ao hla e seus usos. BR0017136A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/004655 WO2001062776A1 (en) 2000-02-23 2000-02-23 Hla binding peptides and their uses

Publications (1)

Publication Number Publication Date
BR0017136A true BR0017136A (pt) 2003-02-25

Family

ID=21741082

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0017136-0A BR0017136A (pt) 2000-02-23 2000-02-23 Peptìdeos de ligação ao hla e seus usos.

Country Status (8)

Country Link
EP (1) EP1263775A4 (pt)
JP (1) JP2003524016A (pt)
CN (1) CN1452634A (pt)
AU (1) AU2000232427A1 (pt)
BR (1) BR0017136A (pt)
CA (1) CA2400215A1 (pt)
MX (1) MXPA02008219A (pt)
WO (1) WO2001062776A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2370413A1 (en) * 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
AU2001242190A1 (en) * 2000-03-31 2001-10-15 Aventis Pasteur Limited Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
EP2332971B1 (en) 2004-06-17 2016-02-17 MannKind Corporation Epitope analogs
US8487076B1 (en) * 2005-01-25 2013-07-16 Nec Corporation HLA-binding peptide, and DNA fragment and recombinant vector coding for said HLA-binding peptide
KR20080028938A (ko) 2005-06-17 2008-04-02 맨카인드 코포레이션 에피토프 유사체
JP5416968B2 (ja) * 2005-06-17 2014-02-12 マンカインド コーポレイション 癌細胞及び腫瘍間質上に発現される優勢及び亜優勢エピトープに対する多価免疫応答を誘発するための方法及び組成物
CN1948333B (zh) * 2005-10-14 2010-12-08 中国人民解放军第二军医大学 一种新的hPEBP4蛋白来源的HLA-A2限制性表位多肽及其应用
US7632814B2 (en) * 2006-09-07 2009-12-15 University Of South Florida HYD1 peptides as anti-cancer agents
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
CA2793838C (en) 2010-03-19 2019-09-17 H. Lee Moffitt Cancer Center & Research Institute, Inc. Integrin interaction inhibitors for the treatment of cancer
WO2012033142A1 (ja) 2010-09-08 2012-03-15 学校法人 埼玉医科大学 Ｃ型肝炎ウイルスリポソームワクチン
US10011635B2 (en) 2013-09-27 2018-07-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cyclic peptide conjugates and methods of use
CA3039322A1 (en) * 2016-10-07 2018-04-12 Enterome S.A. Immunogenic compounds for cancer therapy
WO2018065628A2 (en) 2016-10-07 2018-04-12 Enterome Microbiota sequence variants of tumor-related antigenic epitopes
CN110022894B (zh) 2016-10-07 2024-01-19 恩特罗姆公司 用于癌症疗法的免疫原性化合物
EP3548623A4 (en) 2016-11-30 2020-11-25 Advaxis, Inc. IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND THEIR USE PROCEDURES
CN111655714A (zh) * 2017-11-08 2020-09-11 阿德瓦希斯公司 来自癌症相关蛋白的免疫原性异变肽及其使用方法
EP4169528A1 (en) 2018-04-11 2023-04-26 Enterome S.A. Antigenic peptides for prevention and treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ263050A (en) * 1993-03-05 1997-11-24 Cytel Corp Compositions of immunogenic peptides with hla-a2.1 binding motifs
CN1218406A (zh) * 1996-03-21 1999-06-02 埃皮曼尼公司 Hla－a2.1结合肽及其用途
US6264958B1 (en) * 1996-07-25 2001-07-24 The Johns Hopkins University Genes of kaposi's sarcoma associated herpesvirus
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid

Also Published As

Publication number Publication date
CA2400215A1 (en) 2001-08-30
JP2003524016A (ja) 2003-08-12
EP1263775A1 (en) 2002-12-11
WO2001062776A1 (en) 2001-08-30
MXPA02008219A (es) 2005-06-30
AU2000232427A1 (en) 2001-09-03
CN1452634A (zh) 2003-10-29
EP1263775A4 (en) 2004-10-06

Similar Documents

Publication Publication Date Title
BR0017136A (pt) Peptìdeos de ligação ao hla e seus usos.
BR9708220A (pt) Peptìdios de ligação hla-a2.1 e seus usos
BR9406652A (pt) Composição
AU2001298049A8 (en) Hla class i and ii binding peptides and their uses
ATE512666T1 (de) Hla-bindende peptide und ihre verwendungen
DK0941478T3 (da) Assaymetode for peptidspecifikke T-celler
TR200100936T2 (tr) Terapötik aşılama
ES2184769T3 (es) Metodos y composiciones para microencapsulacion de antigenos para utilizar como vacunas.
BR9610802A (pt) Método para melhoria da resposta imunológica método de preparo de células t de antígeno específico método para induzir tolerância de tecido de enxerto auxiliar de vacina meio de expansão e preparação de células dentríticas população de células dentríticas e respectivo método de preparo método para direcionar células-tronco hematopoiéticas ou células progenitoras a uma linhagem de células dentríticas
ES2177927T3 (es) Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico.
DK1267924T3 (da) Immunterapeutiske metoder og sammensætninger
AU4791901A (en) Compositions and methods for dendritic cell-based immunotherapy
DE69720065D1 (de) Therapeutische anwendungen von antigenen oder epitopen assoziert mit unvollständiger zellulärer peptidprozesierung , z.b.: exprimiert in rma-s zellen transfiziert mit b7-1 gen
ATE429247T1 (de) Hla-bindende peptide und ihre verwendungen
AP2368A (en) Novel expression vectors and uses thereof.
ES2308850T3 (es) Anticuerpos para antigenos de celulas de langerhans de mamiferos y sus usos.
AU2000273396A1 (en) Hla binding peptides and their uses
WO1999047102A3 (en) Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
AR012896A1 (es) Polipeptido flge de helicobacter pylori, composicion de vacuna, uso de dicho polipeptido para la fabricacion de composiciones, metodo de diagnostico invitro, y kit de diagnostico para la deteccion de la infeccion por helicobacter pylori
BR0016740A (pt) Antìgenos de esporozoìto de cryptosporidium

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]